Biomunex announces investment from new shareholders to accelerate its growth and development of its portfolio of innovative bispecific antibodies for cancer immunotherapy

• New shareholders, including private investors and family offices, are investing alongside long-standing shareholders who have been supportive since company's inception.
• This capital increase is fully aligned with Biomunex's growth objectives and follows on the licensing agreement signed with Ipsen in December 2024, for the development of an innovative bispecific antibody in immuno-oncology.
• Biomunex's ambition is to develop a new generation of bi- and multi-specific immunotherapies in oncology, in particular its portfolio of MAIT engagers: bispecific antibodies capable of identifying, mobilizing, and activating MAIT cells, a subpopulation of T cells, to kill cancer cells.

Paris, France, and Cambridge, Massachusetts, USA, September 30rd, 2025 

Biomunex Pharmaceuticals, a French biopharmaceutical company specializing in the development of next generation immunotherapies based on the discovery and development of bi- and multispecific antibodies, today announces a capital increase and the investment from new shareholders in equity, actively supporting its growth trajectory and accelerating the development of its portfolio, particularly its MAIT engagers.

This transaction received support from the company's long-standing shareholders, including Biomunex's management team, as well as a group of new European and international investors. Eurobail, an operator specializing in commercial real estate, hospitality, and investment in innovative companies, is also acquiring a stake in the company.

A financing transaction to accelerate development, following the licensing agreement with Ipsen in immuno-oncology

This financing arises a few months after Biomunex received an upfront payment upon signing an exclusive licensing agreement with Ipsen in December 2024 for the global rights to develop, manufacture, and commercialize BMX-502, a MAIT engager with promising potential in several types of cancer, currently in development for an upcoming Phase 1 trial in humans.

Under the terms of the agreement with Ipsen, Biomunex is eligible to receive up to $610 million, including upfront & milestone payments, in addition to global royalties. This agreement with Ipsen highlights the relevance of Biomunex's MAIT-engager approach and demonstrates the added value of its BiXAb^® bispecific antibody “Plug-and-Play” platform, which is capable of rapidly generating innovative and promising drug candidates.

This equity financing enables Biomunex to accelerate the strengthening of its team, starting in 2025, with a focus on finance and business development, while consolidating its scientific expertise.

MAIT engagers: a new class of antibodies for cancer treatment

Biomunex continues to develop its portfolio of drug candidates, notably its new therapeutic class in immuno-oncology, MAIT-engagers, bispecific antibodies capable of identifying, mobilizing, and activating MAIT cells, which could become a breakthrough approach in the treatment of many cancers.

"Biomunex's recent developments reflect the renewed confidence of our long-standing shareholders in both our innovative technology and our team. The entry of the Eurobail fund along with new shareholders highlights the growing interest in Biomunex and our portfolio of new cancer immunotherapy products, particularly our MAIT engagers," comments Dr. Pierre-Emmanuel Gerard, Founding President and CEO of Biomunex.

Bi- and multi-specific antibodies and T-cell engagers are attracting considerable interest from pharmaceutical companies, with the recent signing of many licensing and partnership agreements, including for Biomunex. "The last few months have marked the beginning of a new chapter in Biomunex's development with the signing of a major agreement with Ipsen, following those signed previously with Sanofi and Onward Therapeutics, demonstrating the team's ability to develop drugs and technologies of interest for the pharmaceutical industry and cancer patients, but also to establish leading licensing agreements and partnerships with the industry," adds Dr. Gerard.

“We are convinced that the innovative immunotherapy developed by Biomunex has the potential to be a breakthrough treatment, capable of redefining the standards of care for both solid and liquid cancers,” concludes Dr. Simon Plyte, Biomunex’s Chief Scientific Officer.

In addition to BMX-502, licensed to Ipsen, Biomunex is developing a portfolio of MAIT-engaging drug candidates and innovative new therapeutic approaches with high potential, based on its proprietary “Plug-and-Play” BiXAb^® platform. This technology enables the generation of breakthrough immunotherapies faster than most other platforms in the field, with excellent drug-like properties and high industrial yield. Biomunex's first BiXAb drug candidate is in Phase 1 clinical development in partnership, as a monotherapy or in combination, in patients with certain solid tumors or hematological malignancies.